Role of TGF-β in vascular development and vascular reactivity

Mineral and Electrolyte Metabolism

Volumn 24, Issue 2-3, 1998, Pages 136-143

  Perrella, Mark A ^a,b,c   Jain, Mukesh K ^a,b,c   Lee, Mu En ^a,b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Development; Reactivity; TGF ; Vasculature

Indexed keywords

ENDOTHELIN; NITRIC OXIDE; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANGIOGENESIS; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CELL DIFFERENTIATION; GENE DELETION; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; YOLK SAC;

ANIMALS; BLOOD VESSELS; GENE DELETION; HUMANS; NITRIC OXIDE SYNTHASE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

VERTEBRATA;

EID: 0031908454     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057361     Document Type: Review

References (58)

1. Brand T, Schneider MD: Transforming growth factor-beta signal transduction. Circ Res 1996; 78:173-179.
2. Brand T, Schneider MD: The TGF-β superfamily in myocardium: Ligands, receptors, transduction, and function. J Mol Cell Cardiol 1995;27:5-18.
3. MacLellan WR, Brand T, Schneider MD: Transforming growth factor-beta in cardiac ontogeny and adaptation. Circ Res 1993;73:783-791.
4. Polyak K: Negative regulation of cell growth by TGF-beta. Biochim Biophys Acta 1996;1242: 185-199.
5. Morisaki N, Kawano M, Koyama N, Koshikawa T, Umemiya K, Saito Y, Yoshida S: Effects of transforming growth factor-beta 1 on growth of aortic smooth muscle cells: Influences of interaction with growth factors, cell state, cell phenotype, and cell cycle. Atherosclerosis 1991;88:227-234.
6. Owens GK, Geisterfer AA, Yang YW, Komoriya A: Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol 1988;107:771-780.
7. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia: Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-461.
8. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L: Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest 1992;90: 1582-1592.
9. Wolf YG, Rasmussen LM, Ruoslahti E: Antibodies against transforming growth factor-beta 1 suppress intimai hyperplasia in a rat model. J Clin Invest 1994;93:1172-1178.
10. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel GJ: Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 1993;90:10759-10763.
11. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schoefield PM, Chauhan A: The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med 1995;1:74-79.
12. Grainger DJ, Witchell CM, Metcalfe JC: Tamoxifen elevates transforming growth factor-β and suppresses diet-induced information of lipid lesions in mouse aorta. Nature Med 1995;1: 1067-1073.
13. Topouzis S, Majesky MW: Smooth muscle Iineage diversity in the chick embryo: Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-beta. Dev Biol 1996;178:430-445.
14. Martin JS, Dickson MC, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ: Analysis of homozygous TGFβ1 null mouse embryos demonstrate defects in yolk sac vasculogenesis and hematopoiesis. Ann NY Acad Sci 1995;752: 300-308.
15. Akhurst RJ, Lehnert SA, Faissner A, Duffie E: TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis. Development 1990;108:645-656.
16. Schmid P, Cox D, Bilbe G, Maier R, McMaster GK: Differential expression of TGF β,1 β2, and β3 genes during mouse embryogenesis. Development 1991;111:117-130.
17. Pelton RW, Dickinson ME, Moses HL, Hogan BL: In situ hybridization analysis of TGFβ3 RNA expression during mouse development: Comparative studies with TGFβ1 and β2. Development 1990;110:609-620.
18. Lawler S, Canadia AF, Ebner R, Shum L, Lopez AR, Moses HL, Wright CVE, Derynck R: The murine type II TGF-β receptor has a coincident embryonic expression and binding preference for TGF-β1. Development 1994; 120:165-175.
19. Kulkami AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Nat Acad Sci USA 1993;90:770-774.
20. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T: Targeted disruption of the mouse transforming growth factor-β gene results in multifocal inflammatory disease. Nature 1992;359:693-699.
21. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ: Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knockout mice. Development 1995;121:1845-1854.
22. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J: Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial-mesenchymal interaction. Nature Genet 1995;11:415-421.
23. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, Ferguson M, Doetschman T: Transforming growth factor-β3 is required for secondary palate fusion. Nature Genet 1995;11:409-414.
24. Oshima M, Oshima H, Taketo MM: TGF-β receptor type II deficiency results in defects in yolk sac hematopoiesis and vasculogenesis. Dev Biol 1996; 179:297-302.
25. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T: TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development 1997;124:2659-2670.
26. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB: Maternal rescue of transforming growth factor-β1 null mice. Science 1994;264:1936-1938.
27. Bonyadi M, Rusholme S, Cousins F, Su HC, Biron CA, Farrall M, Akhurst RJ: Mapping of a genetic modifier of embryonic lethality in TGFβ1 knockout mice. Nature Genet 1997;15: 207-211.
28. Shah NM, Marchoinni MA, Isaacs I, Stroobant PW, Anderson DJ: Glial growth factor restricts mammalian neural crest stem cells to a glial fate. Cell 1994;77:349-360.
29. Shah N, Groves AK, Anderson DJ: Alternative neural crest cell fates are instructively promoted by TGFβ superfamily members. Cell 1996;85:331-343.
30. Stemple D, Anderson DJ: Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell 1992;71:973-985.
31. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Hamaoki M, Kalo H, Yazaki Y: Transforming growth factor-β stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989;159:1435-1440.
32. Kanse SM, Takahashi K, Lam H-C, Rees A, Warren JB, Porta M, Molinatti P, Ghatel M, Boom SR: Cytokine stimulated endothelin release from endothelial cells. Life Sci 1991;48: 1379-1384.
33. Hahn AWA, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Buhler FR: Stimulation of endothelin mRNA and secretion in vascular smooth muscle cells: A novel autocrine function. Cell Regul 1990;1:649-659.
34. Lerman A, Hildebrand FL Jr, Margulies KB, O'Murchu B, Perrella MA, Heublein DM, Schwab TR, Burnett JC Jr: Endothelin: A new cardiovascular regulatory peptide. Mayo Clinic Proc 1990;65:1441-1455.
35. Schiffrin EL: Endothelin: Potential role in hypertension and vascular hypertrophy. Hypertension 1995;25:1135-1143.
36. Lee R, Owens GK, Scott-Burden T, Head RJ, Mulvany MJ, Schiffrin EL: Pathophysiology of smooth muscle in hypertension. Can J Physiol Pharmacol 1995;73:574-584.
37. Agrotis A, Saltis J, Dilley R, Bray P, Bobik A: Transforming growth factor-beta 1 and the development of vascular hypertrophy in hypertension. Blood Pressure 1995;(suppl 2):43-48.
38. Lefer AM, Tsao P, Aoki N, Palladino MA Jr: Mediation of cardioprotection by transforming growth factor-β. Science 1990;249:61-64.
39. Lefer AM, Ma X-L, Weyrich AS, Scalia R: Mechanism of the cardioprotective effect of transforming growth factor-β1 in feline myocardial ischemia and reperfusion. Proc Natl Acad Sci USA 1993;90:1018-1022.
40. G-monomethy-L-arginine by transforming growth factor-β1 in conscious, normal, but not endotoxaemic, rats. Br J Pharmacol 1995;116: 3042-3048.
41. Perrella MA, Yoshizumi M, Fen Z, Tsai J-C, Hsieh C-M, Kourembanas S, Lee M-E: Transforming growth factor-β1, but not dexamethasone, down-regulates nitric oxide synthase mRNA after its induction by interleukin-β1 in rat smooth muscle cells. J Biol Chem 1994;269: 14595-14600.
42. Perrella MA, Patterson C, Tan L, Yet S-F, Hsieh C-M, Yoshizumi M, Lee M-E: Suppression of interleukin-1β-induced nitric-oxide synthase promoter/enhancer activity by transforming growth factor-β1 in vascular smooth muscle cells: Evidence for mechanisms other than NK-κB. J Biol Chem 1996;271:13776-13780.
43. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-1477.
44. Stone R: Search for sepsis drugs goes on despite past failures. Science 1994;264:365-367.
45. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie Q-W, Sokol K, Hutchinson N, Chen H, Mudgett JS: Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995;81:641-650.
46. Wei X-Q, Charles IG, Smith A, Ure J, Feng G-J, Huang F-P, Xu D, Muller W, Moncada S, Leiw FY: Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995;375:408-411.
47. Moncada S, Palmer RM, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
48. Epstein FH: The role of interleukin-1 in disease. N Engl J Med 1993;328:106-113.
49. Ochoa JB, Udekwu AO, Billiar TR, Curran RD, Cerra FB, Simmons RL, Peitzman AB: Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 1991;214:621-626.
50. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990;87:3629-3632.
51. Nava E, Palmer RMJ, Moncada S: Inhibition of nitric oxide synthesis in septic shock: How much is beneficial? Lancet 1991;338:1555-1557.
52. Petros A, Bennett D, Vallance P: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991;338: 1557-1558.
53. Kanno K, Hirata Y, Imai T, Iwashina M, Marumo F: Regulation of inducible nitric oxide synthase gene by interleukin-1 beta in rat vascular endothelial cells. Am J Physiol 1994;267: H2318-H2324.
54. Perrella MA, Hsieh C-M, Lee W-S, Shieh S, Tsai J-C, Patterson C, Lowenstein CJ, Long NC, Haber E, Shore S, Lee M-E: Arrest of endotoxin-induced hypotension by transforming growth factor-β1. Proc Natl Acad Sci USA 1996;93:2054-2059.
55. Vodovotz Y, Bogdan C, Paik J, Xie Q-W, Nathan C: Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor . J Exp Med 1993;178:605-613.
56. Sanai L, Haynes WG, MacKenzie A, Grant IS, Webb DJ: Endothelin production in sepsis and the adult respiratory distress syndrome. Int Care Med 1996;22:52-56.
57. Warner TD, Klemm P: What turns on the endothelins? Inflamm Res 1996;45:51-53.
58. Hollenberg SM, Piotrowski MJ, Parrillo JE: Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to endothelin-1 in septic rats. Am J Physiol 1997;272:R969-R974.